z-logo
open-access-imgOpen Access
Oral posaconazole and bronchoscopy as a treatment for pulmonary mucormycosis in pediatric acute lymphoblastic leukemia patient
Author(s) -
Yan Liang,
Xing Chen,
JinRong Wang,
Chunyan Guo,
Fengqin Liu,
Juan Yang
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024630
Subject(s) - medicine , posaconazole , mucormycosis , bronchoscopy , hematopoietic stem cell transplantation , surgery , radiology , transplantation , dermatology , itraconazole , antifungal
Rationale: Mucormycosis is a rare fungal infection that typically occurs in immunosuppressed patients following chemotherapy or hematopoietic stem cell transplantation. Patient concerns: An 11-year-old child with newly developed acute lymphoblastic leukemia suffered from the paroxysmal left chest pain, fever, and hemoptysis. Diagnoses: We made a histopathologic diagnosis aided by bronchoscopy techniques, which indicated invasive fungal hyphae that are characteristic of mucormycosis. Interventions: The patient was treated with oral posaconazole and repeated bronchoscopy interventions for 4 months. Outcomes: The patient's clinical signs and symptoms and signs were no longer present. The prior lung lesions were also no longer observable using radiologic methods, and a 3-month follow-up with the patient showed no signs of mucormycosis recurrence. Finally, the patient was cured, when the cancer chemotherapy was stopped. Close follow-up for another 2 years showed no evidence of recurrence. Lessons: Mucormycosis diagnosis is difficult as clinical and imaging findings vary. This case demonstrates that posaconazole monotherapy combined with bronchoscopy interventions may be a safe and effective treatment option for pediatric pulmonary mucormycosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here